Title: Review: Pharmacotherapy as part of a weight management programme: a UK perspective
Abstract: Rates of obesity and overweight continue to rise and substantially increase the risk of morbidity and mortality from type 2 diabetes, coronary and mortality from type 2 diabetes, coronary heart disease and stroke. On the other hand, a sustained weight loss of 5—10% in the obese confers marked health benefits. Current strategies for the management of obesity include lifestyle interventions and pharmacotherapy. At present, three drugs are approved for the medical management of obesity in the UK: orlistat, sibutramine and rimonabant. All three agents are efficacious in reducing body weight but by different mechanisms. Although weight loss is an important treatment outcome, a major goal of obesity management should be to improve cardiovascular and metabolic risk factors in order to reduce obesity-related morbidity and mortality. Given the similar levels of weight loss achievable with currently approved agents, treatment decisions should include careful assessment of the effects of these agents on cardiovascular and metabolic risk factors and on their long-term safety profiles. Br J Diabetes Vasc Dis 2007;7:268-77
Publication Year: 2007
Publication Date: 2007-11-01
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot